The skin barrier is broadly composed of two elements—a physical barrier mostly localised in
the epidermis, and an immune barrier localised in both the dermis and epidermis. These two …

Introduction Psoriasis management is challenging, especially in pediatric age for different
factors. The introduction of biologic drugs and oral small molecules (OSM) revolutionized the …

Objective To evaluate the randomized controlled trials (RCTs) of Curcumin and Curcuma
longa Extract in the treatment of autoimmune diseases. Methods Databases such as …

Over the past three decades, many methods have been developed to evaluate levels of
biomarkers in autoimmune diseases. Early investigations have shown that some biomarkers …

Abstract Sphingosine-1-phosphate (S1P) is a bioactive lipid metabolite that exerts its actions
by engaging 5 G-protein-coupled receptors (S1PR1-S1PR5). S1P receptors are involved in …

An association of melatonin levels with age disease initiation of autoimmune diseases and
pineal calcification was reported while an inverse association between melatonin levels and …

Psoriasis is a chronic, immune-mediated inflammatory disease that affects around 125
million people worldwide. Several studies concerning the gut microbiota composition and its …

Risankizumab is a humanized IgG monoclonal antibody inhibitor of IL23 and has been
recently approved by the EMA and the FDA for the treatment of moderate to severe plaque …

Psoriasis is one of the most common immune-mediated chronic inflammatory skin disorders,
involving hyperproliferative keratinocytes and infiltration of T cells, dendritic cells …

Autoimmunity refers to the phenomenon that the body's immune system produces antibodies
or sensitized lymphocytes to its own tissues to cause an immune response. Immune …